Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
activist, advocating, affiliate, body, book, CAD, clastogenic, clause, confound, consecutive, deprive, developmental, dordaviprone, double, eleven, endometrial, enriched, Eradication, excise, explored, France, franchise, Gustave, HGG, IDMC, IIT, INN, instance, IRA, irresponsible, Lansing, LDT, led, leverage, leveraged, LGG, metastatic, misconduct, modest, mutagenic, mutually, NANO, nanomolar, neurologic, Nonproprietary, nonsalable, novated, novation, Oncoceutic, outpace, Pacific, path, PCT, PHAC, poor, poster, potency, pre, predominantly, prodrug, QoL, radiotherapy, RANO, ratably, regimen, resume, retroactive, Roussy, Rubric, shift, shortly, SNO, transferor, unplanned, upside, volunteer, weighing, world
Removed:
acute, AdAPT, AdV, Allergy, anthracycline, API, arbitration, Assistant, ban, BBA, BCV, Berrey, bioterror, biowarfare, Bipartisan, black, blinding, bone, box, boxed, branded, bringing, budget, Cadillac, calendar, California, category, chemoresistance, Chief, children, circumvent, clear, comparative, compare, composition, Concurrently, consolidation, constituted, constrained, cure, cytarabine, cytotoxic, deeper, define, demonstrating, DMC, DoD, Dr, EFS, elastase, emergency, enasidenib, enzyme, Eurasia, Eurasian, expensing, experimental, feasible, febrile, figure, finalization, fire, forecasted, gap, gemtuzumab, genetic, gilteritinib, glasdegib, glycosaminoglycan, graphically, HCT, heightened, hematologic, hypomethylating, hypothetical, implementation, implicated, inducement, induction, infection, insolvency, insurer, intermediate, IPO, irrevocable, ivosidenib, leukemia, leukemic, lift, liver, marrow, Michelle, midostaurin, MMA, Modernization, MRD, myeloid, Mylotarg, negotiated, neutropenia, Nevada, ninety, offered, outbreak, outpatient, pause, pilot, placement, platelet, platform, police, posting, preceding, proposal, protein, Pyramid, quiescent, rating, reconsideration, removing, render, repeal, repealing, replacement, representation, residual, resignation, resigned, resistance, restructured, revalidation, RFP, RFS, ruling, schematic, Secretary, singular, SPL, standardized, stem, step, stockpiling, sue, suggested, tier, transferring, transplant, transplantation, Trump, Unaudited, unblinded, unblinding, undergone, uproleselan, variable, venetoclax
Filing tables
Filing exhibits
Related press release
Associated CMRX transcripts
CMRX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1.Registration Statement (Form S-8 No. 333-187860) pertaining to the 2002 Equity Incentive Plan, 2012 Equity Incentive Plan, 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of Chimerix, Inc.,
2.Registration Statement (Form S-8 Nos. 333-194408, 333-202582, 333-209802, 333-216396, 333-223344, 333-230071, 333-233115, 333-236610, 333-253494, and 333-263131) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of Chimerix, Inc., and
3.Registration Statement (Form S-3 No. 333-244146 and 333-255810) of Chimerix, Inc.;
of our reports dated March 2, 2023 with respect to the consolidated financial statements of Chimerix, Inc. and the effectiveness of internal control over financial reporting of Chimerix, Inc. included in this Annual Report (Form 10-K) of Chimerix, Inc. for the year ended December 31, 2022.
/s/ Ernst & Young LLP | ||||||||
Raleigh, North Carolina | ||||||||
March 2, 2023 |